أعرض في EDS

Analysis of risk factors for lenalidomide-associated skin rash in patients with multiple myeloma

التفاصيل البيبلوغرافية
العنوان: Analysis of risk factors for lenalidomide-associated skin rash in patients with multiple myeloma
المؤلفون: Shin Ohara, Shiro Ide, Yasuo Nishigami, Masao Hagihara, Mitsuo Mita, Keisuke Takabatake, Tomiyuki Sugi, Morihiro Inoue, Homare Hanai, Tomoyuki Uchida, Hirohisa Saigo
المصدر: Leukemia & Lymphoma. 62:1405-1410
بيانات النشر: Informa UK Limited, 2021.
سنة النشر: 2021
مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, Dexamethasone, 03 medical and health sciences, 0302 clinical medicine, Risk Factors, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, In patient, Risk factor, Lenalidomide, Multiple myeloma, Aged, Retrospective Studies, business.industry, Medical record, Hematology, Exanthema, medicine.disease, Rash, humanities, 030220 oncology & carcinogenesis, medicine.symptom, Multiple Myeloma, business, 030215 immunology, medicine.drug
الوصف: The aim of the present study was to identify the risk factors for lenalidomide (Len)-associated skin rash. We retrospectively investigated the medical records of 144 multiple myeloma patients treated with Len-containing therapies. A total of 64 of 144 patients included in the study had skin rash (44.4%). 50 patients developed skin rash within 4 weeks of starting Len treatment. Further, in 29 patients, the skin rash appeared at an early stage (within 1 week) after treatment initiation. Univariate analysis revealed that the risk of skin rash significantly increased in patients with advanced age (
تدمد: 1029-2403
1042-8194
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9049962f0a18eb51ac8ba8640b544701
https://doi.org/10.1080/10428194.2021.1876867
رقم الأكسشن: edsair.doi.dedup.....9049962f0a18eb51ac8ba8640b544701
قاعدة البيانات: OpenAIRE
الوصف
تدمد:10292403
10428194